Please try another search
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Stelios Papadopoulos | 73 | 2009 | Independent Chairman of the Board |
Joseph P. Hagan | 54 | 2016 | CEO & Director |
David Baltimore | 85 | 2009 | Chairman of the Scientific Advisory Board & Independent Director |
William H. Rastetter | 75 | 2013 | Independent Director |
Timothy Michael Wright | 67 | 2016 | Member of the Scientific Advisory Board |
Hugh Rosen | 64 | 2016 | Independent Director |
Thomas H. Tuschl | - | - | Member of the Scientific Advisory Board |
Markus Stoffel | - | - | Member of the Scientific Advisory Board |
Pascale Witz | 56 | 2017 | Independent Director |
Jason R. Nunn | 53 | 2019 | Independent Director |
Alice Shih-hou Huang | 83 | 2021 | Independent Director |
Kathryn J. Collier | 55 | 2018 | Independent Director |
Preston S. Klassen | 54 | 2023 | President, Head of Research & Development and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review